NCT05583422View on ClinicalTrials.gov

Evaluating a Pharmacogenetic Testing Panel in Patients Suspected to be at Increased Risk for Pharmacogenetics-related AEs While Receiving Fluoropyrimidine or Irinotecan Therapy

CompletedOBSERVATIONAL
Enrollment

16

Participants

Timeline

Start Date

August 18, 2023

Primary Completion Date

June 17, 2024

Study Completion Date

June 17, 2024

Conditions
Cancer
Interventions
GENETIC

DPYD or UGT1A1 variants

any CLIA certified lab can be used for confirmatory testing after patients have been identified through Michigan Genomics Initiative (MGI)

Trial Locations (1)

48109

University of Michigan Rogel Cancer Center, Ann Arbor

All Listed Sponsors
lead

University of Michigan Rogel Cancer Center

OTHER